Sutro Biopharma
STRO
78 hedge funds and large institutions have $358M invested in Sutro Biopharma in 2026 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 9 closing their positions.
453% more capital invested
Capital invested by funds: $64.8M → $358M (+$294M)
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
80.25% more ownership
Funds ownership: 6.58% → 86.83% (+80%)
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
24% more funds holding
Funds holding: 63 → 78 (+15)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$22.6M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$15.5M |
| 3 |
O
OrbiMed
New York
|
+$14.5M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.76M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$2.81M |
| 3 |
EP
Eversept Partners
New York
|
-$2.18M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.62M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
76
Arax Advisory Partners
Denver,
Colorado
| $75 | +$687 | +38 | +1,267% |
|
77
Fifth Third Bancorp
Cincinnati,
Ohio
| $50 | +$36 | +2 | New |
|
|
VPC
78
Vestal Point Capital
New York
| – | -$2.81M | -243,000 | Closed |
|
|
TCM
79
Tang Capital Management
San Diego,
California
| – | -$1.62M | -139,617 | Closed |
|
|
SSC
80
Spruce Street Capital
New York
| – | -$875K | -75,594 | Closed |
|
|
SC
81
Shay Capital
New York
| – | -$281K | -24,255 | Closed |
|
82
Two Sigma Advisers
New York
| – | -$203K | -17,580 | Closed |
|
83
JP Morgan Chase
New York
| – | -$8.57K | -741 | Closed |
|
84
Wells Fargo
San Francisco,
California
| – | -$1.16K | -100 | Closed |
|
|
EP
85
Essential Partners
Rancho Santa Fe,
California
| – | -$46 | -4 | Closed |
|
86
Group One Trading
Chicago,
Illinois
| – | -$23 | -2 | Closed |
|
87
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$18 | +1 | +9% |
|
STRO Hedge Fund Activity: Q1 2026 in Review
78 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2026, worth a combined $358M — up 453% from $64.8M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new STRO positions and 9 closed out — a net gain of 17 holders — while 23 added to existing stakes and 13 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $22.6M. The largest seller was Millennium Management, cutting an estimated $3.76M.
- 78 institutional investors held Sutro Biopharma (STRO) as of Q1 2026, up from 63 in Q4 2025.
- Funds reported $358M of Sutro Biopharma stock for Q1 2026, up 453% quarter-over-quarter.
- 26 funds opened new Sutro Biopharma positions in Q1 2026 and 9 closed out, a net change of +17 holders.
- The largest Sutro Biopharma buyer in Q1 2026 was BVF Inc, an estimated $22.6M added.
- The largest Sutro Biopharma seller in Q1 2026 was Millennium Management, an estimated $3.76M sold.
Based on aggregated 13F filings for Q1 2026.